OncRef

Clinical Trial: NCT04526691

Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 1

Lead Sponsor:Daiichi Sankyo
Information Provided By:Daiichi Sankyo
Last Update Posted:2026-05-15

Study Overview

Brief Summary

This study will assess safety and treatment activity of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum chemotherapy in participants with advanced or metastatic non-small cell lung cancer.

Official Title

Phase 1b, Multicenter, Open-label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)

Conditions

Advanced or Metastatic NSCLC

Intervention / Treatment

  • Drug: Datopotamab deruxtecan
  • Drug: KEYTRUDA®
  • Drug: Carboplatin
  • Drug: Cisplatin

Other Study ID Numbers

  • DS1062-A-U102
  • 2020-006047-25
  • jRCT2031200193
  • KEYNOTE-B43
  • MK-3475-B43

Start Date (Actual)

2020-09-15

Primary Completion Date (Actual)

2024-04-14

Study Completion Date (Estimated)

2026-12-31

Enrollment (Actual)

145

Study Type

Interventional

Phase

Phase 1